Right Drug. Right Dose. Right Patient.
Every patient responds to medications differently. Genetic variations can significantly influence how drugs are metabolized, affecting both therapeutic efficacy and the risk of adverse drug reactions (ADRs).
Our PGx SNP + CNV Real-Time PCR Panel provides comprehensive pharmacogenomic profiling by detecting both single nucleotide polymorphisms (SNPs) and copy number variations (CNVs) in clinically actionable pharmacogenes. These insights help clinicians personalize medication selection and dosing to improve safety and therapeutic outcomes.
of individuals carry at least one actionable pharmacogenetic variant, meaning genetic differences may influence the metabolism or effectiveness of one or more commonly prescribed medications.
Our PGx panel evaluates clinically relevant pharmacogenes associated with:
Genes involved in Phase I and Phase II metabolism influence how quickly or slowly patients process medications.
Examples include genes affecting:
Detects clinically important sequence variants that may result in:
These genetic differences may alter medication response or increase toxicity risk.
Unlike SNP testing alone, our PGx panel also evaluates gene copy number changes.
CNV detection is particularly valuable because:
This comprehensive approach provides a more complete assessment of a patient’s pharmacogenomic profile.
Pharmacogenomic results help clinicians identify medications more likely to be:
Genetic results support individualized dosing recommendations that may reduce:
Adverse drug reactions remain a leading cause of emergency department visits and hospitalizations.
PGx testing helps identify patients at increased genetic risk before therapy begins, supporting safer prescribing decisions.
Personalized prescribing may contribute to:
Particularly valuable for patients taking multiple medications.
Helps clinicians evaluate:
A patient’s pharmacogenomic profile generally does not change over time.
Results can be referenced whenever:
Optimize prescribing across common chronic medications.
Support treatment decisions for antidepressants, antipsychotics, mood stabilizers, and ADHD medications.
Guide opioid and non-opioid therapy based on metabolic phenotype.
Assist with antiplatelet agents, anticoagulants, beta blockers, and lipid-lowering therapies.
Support pharmacogenomic-informed treatment planning for select chemotherapeutic and supportive care agents.
Personalize therapy for epilepsy, migraine, neuropathy, and movement disorders.
Reduce adverse drug events in older adults receiving multiple medications.
Consider pharmacogenomic testing for patients who:
Our PGx SNP + CNV Real-Time PCR Panel empowers healthcare providers with clinically actionable genetic information to help optimize medication therapy throughout a patient’s lifetime.
By integrating SNP and CNV analysis into a single assay, clinicians gain a more comprehensive understanding of drug metabolism that supports safer, more effective, andindividualized treatment.
PGx SNP + CNV Real-Time PCR Panel Empowering Precision Medicine Through Actionable Genetics
Please Note: Standard 24-hour turnaround times do not apply to PGx testing. PGx results are available within 5–7 business days from specimen receipt.
